Raymond James resumed coverage on ACADIA Pharmaceuticals
$ACAD
Biotechnology: Pharmaceutical Preparations
Health Care
Raymond James resumed coverage of ACADIA Pharmaceuticals with a rating of Mkt Perform
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/10/2024 | Mkt Perform | Raymond James | |
| 8/7/2024 | $28.00 → $20.00 | Overweight → Equal-Weight | Morgan Stanley |
| 6/27/2024 | $31.00 | Outperform | BMO Capital Markets |
| 3/12/2024 | $36.00 → $32.00 | Buy | Needham |
| 3/12/2024 | $39.00 → $25.00 | Buy → Neutral | Mizuho |
| 1/30/2024 | $40.00 | Outperform | Robert W. Baird |
| 1/24/2024 | $37.00 | Hold → Buy | Needham |
| 12/19/2023 | $31.00 → $40.00 | Equal-Weight → Overweight | Morgan Stanley |
4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)
4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)
3 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)
- 3Q24 total revenues of $250.4 million, up 18% year-over-year - 3Q24 NUPLAZID® (pimavanserin) net product sales of $159.2 million, up 10% year-over-year - 3Q24 DAYBUE™ (trofinetide) net product sales of $91.2 million, up 36% year-over-year Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced its financial results for the third quarter ended September 30, 2024. "The success of Acadia's two growing commercial franchises is clearly reflected in our third quarter 2024 results, where we delivered $250.4 million in total revenues, putting us on track to reach an impressive milestone of more than $1 billion in annualized sales in 2025," said Catherine Owen Adams, Chief Executive Officer.
Company to host conference call and webcast on Wednesday, November 6, 2024, at 4:30 p.m. Eastern Time Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that it will report third quarter financial results on Wednesday, November 6, 2024, after the close of the U.S. financial markets. Acadia's management team will also host a conference call and webcast on November 6, 2024, at 4:30 p.m. Eastern Time to discuss financial results and operations. The conference call will be available on Acadia's website, Acadia.com under the investors section and will be archived there until December 6, 2024. The conference call may also be accessed by registering for the call here. Once registered, par
- Second quarter total net product sales of $242.0 million, up 46% year-over-year Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced its financial results for the second quarter ended June 30, 2024. "In the second quarter of 2024, Acadia delivered $242.0 million in net product sales, highlighted by 11% year-over-year growth in NUPLAZID net sales and 11% sequential growth in DAYBUE net sales," said Steve Davis, Chief Executive Officer. "Additionally, we are advancing enrollment in our Phase 3 trial in Prader-Willi syndrome and our Phase 2 / Phase 3 program in Alzheimer's disease psychosis. With two successful commercial products, a strong pipeline of late and early-stage assets an
8-K - ACADIA PHARMACEUTICALS INC (0001070494) (Filer)
S-8 - ACADIA PHARMACEUTICALS INC (0001070494) (Filer)
8-K - ACADIA PHARMACEUTICALS INC (0001070494) (Filer)
Submission status for ACADIA PHARMS INC's drug NUPLAZID (SUPPL-9) with active ingredient PIMAVANSERIN TARTRATE has changed to 'Approval' on 09/15/2023. Application Category: NDA, Application Number: 210793, Application Classification: Efficacy
Submission status for ACADIA PHARMS INC's drug NUPLAZID (SUPPL-12) with active ingredient PIMAVANSERIN TARTRATE has changed to 'Approval' on 09/15/2023. Application Category: NDA, Application Number: 207318, Application Classification: Efficacy
Submission status for ACADIA PHARMS INC's drug DAYBUE (ORIG-1) with active ingredient TROFINETIDE has changed to 'Approval' on 03/10/2023. Application Category: NDA, Application Number: 217026, Application Classification: Type 1 - New Molecular Entity
Throughout the last three months, 13 analysts have evaluated ACADIA Pharmaceuticals (NASDAQ:ACAD), offering a diverse set of opinions from bullish to bearish. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 6 4 0 0 Last 30D 0 1 0 0 0 1M Ago 0 2 0 0 0 2M Ago 0 0 0 0 0 3M Ago 3 3 4 0 0 Analysts have set 12-month price targets for ACADIA Pharmaceuticals, revealing an average target of $27.69, a high estimate of $37.00, and a low estimate of $19.00. A decline of 5.91% from the prior ave
Morgan Stanley analyst Jeffrey Hung maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Overweight and lowers the price target from $30 to $28.
Raymond James resumed coverage of ACADIA Pharmaceuticals with a rating of Mkt Perform
Morgan Stanley downgraded ACADIA Pharmaceuticals from Overweight to Equal-Weight and set a new price target of $20.00 from $28.00 previously
BMO Capital Markets initiated coverage of ACADIA Pharmaceuticals with a rating of Outperform and set a new price target of $31.00
- Ms. Owen Adams brings over 25 years of pharmaceutical industry experience including senior commercial leadership roles with Bristol Myers Squibb and Johnson & Johnson Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that Catherine Owen Adams has succeeded Steve Davis as Chief Executive Officer (CEO) and joined the Acadia Board of Directors. "We are excited to welcome Catherine Owen Adams as the new CEO of Acadia," said Stephen Biggar, M.D., Ph.D., Chair of the Board of Directors. "Catherine is a proven global leader with a distinguished record of accomplishment of driving growth and innovation in the pharmaceutical industry. Her strategic vision, deep expertise, and unwavering
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced the appointment of Dr. Elizabeth H. Z. Thompson as Executive Vice President, Head of Research and Development. Dr. Thompson will lead research and development at Acadia and serve as a member of the company's Executive Leadership Team, reporting to Steve Davis, Chief Executive Officer of Acadia. "Liz is a preeminent drug research and development leader with extensive experience in the advancement and commercialization of first in class therapies," said Steve Davis, Chief Executive Officer. "Her passion and expertise for developing new medicines that address areas of high unmet need will be a huge asset to Acadia and an important add
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced the appointment of Albert Kildani as Senior Vice President, Investor Relations and Corporate Communications. Mr. Kildani will be responsible for leading investor relations and corporate communications and serve as a member of the company's Executive Management Committee. He will report to Mark Schneyer, Executive Vice President, Chief Financial Officer of Acadia. "Al brings to Acadia a strong track record of leading investor relations and corporate communications functions at numerous growth-oriented companies across the healthcare industry," said Mark Schneyer, Executive Vice President, Chief Financial Officer. "His deep experienc
SC 13G - ACADIA PHARMACEUTICALS INC (0001070494) (Subject)
SC 13G/A - ACADIA PHARMACEUTICALS INC (0001070494) (Subject)
SC 13G/A - ACADIA PHARMACEUTICALS INC (0001070494) (Subject)
- 3Q24 total revenues of $250.4 million, up 18% year-over-year - 3Q24 NUPLAZID® (pimavanserin) net product sales of $159.2 million, up 10% year-over-year - 3Q24 DAYBUE™ (trofinetide) net product sales of $91.2 million, up 36% year-over-year Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced its financial results for the third quarter ended September 30, 2024. "The success of Acadia's two growing commercial franchises is clearly reflected in our third quarter 2024 results, where we delivered $250.4 million in total revenues, putting us on track to reach an impressive milestone of more than $1 billion in annualized sales in 2025," said Catherine Owen Adams, Chief Executive Officer.
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that it entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $150 million upon the closing of the transaction. Acadia was granted the PRV in March 2023 following approval by the U.S. Food and Drug Administration (FDA) of DAYBUE™ (trofinetide) for the treatment of Rett syndrome. DAYBUE was initially licensed by Acadia from Neuren Pharmaceuticals Limited in August 2018. Pursuant to the license agreement, Acadia is required to pay Neuren one-third of the net proceeds. Acadia plans to invest proceeds from the sale of the PRV to support its commercial operations, R&D pro
Company to host conference call and webcast on Wednesday, November 6, 2024, at 4:30 p.m. Eastern Time Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that it will report third quarter financial results on Wednesday, November 6, 2024, after the close of the U.S. financial markets. Acadia's management team will also host a conference call and webcast on November 6, 2024, at 4:30 p.m. Eastern Time to discuss financial results and operations. The conference call will be available on Acadia's website, Acadia.com under the investors section and will be archived there until December 6, 2024. The conference call may also be accessed by registering for the call here. Once registered, par